Month: February 2023

Refreshing USA LLC, a National US Independent Automated Unattended Retailer, Announces Plans to Go Public via Merger with Integrated Wellness Acquisition Corp

Written by Customer Service on February 10, 2023. Posted in Public Companies.

Refreshing USA, LLC (“Refreshing USA”) has entered into a merger agreement with Integrated Wellness Acquisition Corp (NYSE: WEL) The combined company, which will be named Refreshing USA, will have an implied Pro-forma enterprise value of approximately $197.97 million with up to approximately $105.78 million in additional cash, assuming no redemptions by Integrated Wellness’ public shareholders Current Refreshing USA shareholders will retain 100% of their equity and will continue to own approximately 52.67% of the combined company on a pro forma basis, assuming no redemptions by Integrated Wellness’ public shareholdersEVERETT, WA, Feb. 10, 2023 (GLOBE NEWSWIRE) — Refreshing USA, founded by Ryan Wear, who has operated in the automated and unattended retail services industry since 1996, established Refreshing USA in 2020 with...

Potbelly Corporation Announces Replacement of Short-Term Revolver with $25 Million Five-Year Term Loan

Written by Customer Service on February 10, 2023. Posted in Public Companies.

New term loan provides Potbelly financial flexibility to support the Company through next phase of growth CHICAGO, Feb. 10, 2023 (GLOBE NEWSWIRE) — Potbelly Corporation (NASDAQ: PBPB) (“Potbelly” or the “Company”), the iconic neighborhood sandwich shop, today announced it closed on a new $25 million senior secured term loan (the “Facility”) that matures on February 7, 2028, led by Sagard. Steve Cirulis, Chief Financial Officer of Potbelly, commented, “Potbelly’s new five-year term loan replaces our short-term revolving credit facility and will provide the Company with enhanced financial flexibility, which is particularly important as we execute against our Five-Pillar Strategy and make additional progress towards our medium and long-term growth objectives. We are excited to add Sagard as a lending partner and believe that completing...

Bon Natural Life Limited Announces Record-Setting Full Fiscal Year 2022 Results

Written by Customer Service on February 10, 2023. Posted in Public Companies.

Revenue increased by 17.3% to $29.9 million. Delivered full fiscal year 2022 net income of $6.2 million, or $0.74 per diluted share.Xian, China, Feb. 10, 2023 (GLOBE NEWSWIRE) — Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced its 2022 annual financial results for the fiscal year ended September 30, 2022. FY 2022 Financial HighlightsTotal net revenues were US$29.9 million, representing a 17.3% increase from US$25.5 million for the same period in 2021. Gross profit increased by 32.5% to US$9.4 million from US$7.1 million for the same period in 2021. Gross margin was 31.5%, an increase by 3.6% from 27.9% for the same period in 2021. Revenues and gross profit of our...

Smart Pills Technology Market is Projected Surpass USD 3077.22 Million by 2028 by growing at a CAGR of 22% from 2022-2028; Rising Demand for Minimally Invasive Devices for Accurate Therapeutic Treatment Propels Market Growth

Written by Customer Service on February 10, 2023. Posted in Mergers And Acquisitions.

SkyQuest’s research on the smart pills technology market presents a comprehensive analysis of the market’s latest trends and growth prospects. The study is based on thoroughly examining reliable and trustworthy data sources and aims to provide a clear picture of the market’s future trajectory. The report focuses on forecasting future market trends, estimating the size of key market segments, and evaluating the growth potential of regional markets Westford USA, Feb. 10, 2023 (GLOBE NEWSWIRE) — North America is the prominent region in the global smart pills technology market, thanks to favorable reimbursement policies and streamlined regulatory processes for capsule endoscopy. As per SkyQuest’s findings, there is a growing need for smart pills in the region, particularly in the United States, owing to the...

Biopharmaceutical Analytical Testing Services Market is anticipated to Cross USD 11.67 Billion by 2028 with a CAGR of 6.36% during 2022 – 2028; Huge Rise in Outsourcing of Analytical Testing Services Emerges as the Key Trend

Written by Customer Service on February 10, 2023. Posted in Mergers And Acquisitions.

SkyQuest’s latest market research report is a valuable resource for businesses seeking a competitive edge in the biopharmaceutical analytical testing services market. The report offers in-depth insights into the latest market trends, demographic changes, and customer preferences, helping companies to make informed marketing decisions. With the market being highly competitive, it’s essential to have a well-informed marketing strategy to succeed. The report provides valuable information that can be used to form a sound marketing plan and implement effective strategies. Westford USA, Feb. 10, 2023 (GLOBE NEWSWIRE) — North America’s biopharmaceutical analytical testing services market has seen significant growth in recent years. Such growth is driven by the increasing use of FTE (full-time equivalent) agreements for...

Medical Practice Management Software Market is Poised to Reach USD 23.46 Billion by 2028 with a CAGR of over 8.8% from 2022-2028; Growing Demand for Improved Healthcare Provisions to Boost the Market Growth

Written by Customer Service on February 10, 2023. Posted in Mergers And Acquisitions.

The medical practice management software market is a rapidly growing industry, and it is crucial for market participants and stakeholders to stay informed about the latest trends and developments. This is where the recent research study from SkyQuest can be of great assistance. The research report provides comprehensive data on market segments, sub-segments, and geographies, helping players understand the market landscape better. As a result, the study can help market players make informed decisions about product optimization, targeted regions, and supply chain solutions, ultimately leading to increased market share and revenue growth. Westford USA, Feb. 10, 2023 (GLOBE NEWSWIRE) — The North American region has seen a significant increase in medical practice management software (MPMS) adoption in recent years. Such progress can...

According to MarketsandMarkets™ Report – The Cell Culture Market is Anticipated to Achieve $41.3 billion by 2026

Written by Customer Service on February 10, 2023. Posted in Mergers And Acquisitions.

Chicago, Feb. 10, 2023 (GLOBE NEWSWIRE) — As per the new market research report published by MarketsandMarkets, “Cell Culture Market Size, Growth by Product (Consumables (Media, Serum, Reagent, Vessels), Equipment (Bioreactor, Centrifuge, Incubator)), Application (Vaccines, mAbs, Diagnostics, Tissue Engineering), End User (Pharma, Biotech, Hospital) – Global Forecast to 2026“, the global Cell Culture market in terms of revenue was estimated to be worth $22.8 billion in 2021 and is poised to reach $41.3 billion by 2026, growing at a CAGR of 12.6% from 2021 to 2026. Browse in-depth TOC on “Cell Culture Market“334 – Tables48 – Figures398 – Pages Download an Illustrative Overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=559 Cell Culture Market Report Scope:Report Coverage...

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

Written by Customer Service on February 10, 2023. Posted in Earnings Releases And Operating Results.

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022. Management Commentary “We were pleased to close our previously announced merger in January 2023,” said Kenneth A. Berlin, President and Chief Executive Officer of the Company. “Our immediate priorities include executing on Part B of the ongoing registration-enabling RINGSIDE study evaluating AL102 in desmoid tumors. We believe that AL102 has best in class potential and, if approved, may have important clinical advantages including safety, convenient once daily dosing and lower pill burden. For AL101, we expect to gain clarity this...

REMINDER – Saputo Inc.: Fiscal 2023 Third Quarter Results

Written by Customer Service on February 10, 2023. Posted in Earnings Releases And Operating Results.

MONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) — Saputo Inc. (TSX:SAP) – Saputo will release its fiscal 2023 third quarter financial results on Thursday, February 9, 2023. A press release will be issued after markets close, and a conference call is scheduled on Friday, February 10, 2023, at 8:30 a.m. (Eastern Time) to discuss the Company’s results. The webcast will begin with a short presentation followed by a question and answer period. The speakers will be Mr. Lino A. Saputo, Chair of the Board, President and Chief Executive Officer and Mr. Maxime Therrien, Chief Financial Officer and Secretary. To participate:Webcast: https://www.gowebcasting.com/12421Presentation slides will be included in the webcast and can also be accessed in the “Investors” section of Saputo’s website (www.saputo.com), under “Calendar of Events”.Conference...

Gencor Releases First Quarter Fiscal 2023 Results

Written by Customer Service on February 10, 2023. Posted in Earnings Releases And Operating Results.

ORLANDO, Fla., Feb. 10, 2023 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenues increased 28.4% to $25,825,000 for the quarter ended December 31, 2022 compared to $20,106,000 for the quarter ended December 31, 2021, due to higher contract equipment and parts sales. Gross margins were 22.5% for the quarter ended December 31, 2022 compared to 18.4% for the quarter ended December 31, 2021 on increased production and favorable price realization. Product engineering and development expenses decreased $452,000 to $897,000 for the quarter ended December 31, 2022, as compared to $1,349,000 for the quarter ended December 31, 2021, due primarily to lower headcount. Selling, general and administrative (“SG&A”) expenses decreased by $600,000 to $2,799,000 for the quarter...

Month: February 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals